期刊文献+

地西他滨联合CAG方案治疗老年急性髓系白血病临床疗效观察 被引量:10

Clinical observation of combination of CAG with west shore in the treatment of elderly patients with acute myeloid leukemia
在线阅读 下载PDF
导出
摘要 目的观察地西他滨联合CAG方案治疗老年急性髓系白血病的临床疗效。方法选取2015年1月~2016年1月我院住院治疗的老年急性髓系白血病患者60例,采用随机数字表法分为观察组和对照组,每组各30例,对照组采取CAG化疗方案治疗,观察组采用地西他滨联合CAG方案治疗,比较两组患者治疗后的临床疗效及不良反应。结果观察组患者治疗后的总有效率达80.0%,对照组患者治疗后的总有效率达50.0%,两组组间疗效比较具有统计学差异(P<0.05)。观察组治疗后白细胞减少、血小板减少、肺部感染、肝功能损害、恶心呕吐、脱发、腹泻的发生率显著低于对照组,两组组间比较具有统计学差异(P<0.05)。结论地西他滨联合CAG方案治疗老年急性髓系白血病临床疗效明显提高,不良反应明显降低,具有较好的临床效果,值得广泛推广和应用。 Objective To observe the clinical effect of combination of CAG with west shore in the treatment of elderly patients with acute myeloid leukemia.Methods60elderly patients with acute myeloid leukemia in our hospital from January2015to January2016were selected and randomly divided into observation group and control group with30cases in each group.Patients in control group were treated with CAG chemotherapy treatment,and patients in observation group were treated with decitabine combined with CAG regimen.The clinical curative effect and adverse reaction of the two groups after treatment were compared.Results The total effective rate of the observation group was80%,and the total effective rate of the control group after treatment was up to50%.There was significant difference between the two groups(P<0.05).The incidence rates of leukopenia,thrombocytopenia,pulmonary infection,liver damage,nausea and vomiting,alopecia and diarrhea in observation group after the treatment were significantly lower than the control group,there was significant difference between the two groups(P<0.05).Conclusion The clinical efficacy of CAG combined with chemotherapy in the treatment of elderly patients with acute myeloid leukemia is significantly improved,and the adverse reactions are significantly reduced.It has good clinical effect,and it is worth popularizing and applying widely.
作者 陈光 陆屹峰 朱玲玲 董莉 CHEN Guang;LU Yifeng;ZHU Lingling;DONG Li(Blood Specialty, the Second Affiliated Hospital of Mudanjiang Medical University, Heilongjiang, Mudanjiang 157000, China;Blood Specialty, Hongqi Affiliated Hospital of Mudanjiang Medical University, Heilongjiang,Mudanjiang 157000, China;Department of Pediatrics, the Second Affiliated Hospital of Mudanjiang Medical University, Heilongjiang, Mudanjiang 157000, China)
出处 《中国医药科学》 2017年第11期62-64,151,共4页 China Medicine And Pharmacy
关键词 老年急性髓系白血病 地西他滨 CAG方案 不良反应 Acute myeloid leukemia in elderly patients CAG regimen Adverse reaction
作者简介 通讯作者
  • 相关文献

参考文献18

二级参考文献169

  • 1张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,1999:131-132.
  • 2Jackson G,Taylor P,Smith GM,et al.A multicentre,open,noncomparative phase Ⅱ study of a combination of fludarabine phosphate,cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anemia with excess of blasts in transformation. Br J Haematol,2001,112:127-137.
  • 3Carney DA,Westerman DA,Tam CS,et al.Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.Leukemia,2010,24:2056-2062.
  • 4Lakshmikuttyamma A,Scott SA,DeCoteau JF,et al.Reexpression of epigenetically silenced AML tumorsuppressor genes by SUV39H1 inhibition.Oncogene,2010,29:576-588.
  • 5Sigalotti L,Altomonte M,Colizzi F,et al.5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies:a multimechanism therapeutic approach? Blood,2003,101:4644-4646.
  • 6LUBBERT M,RUTER B,SCHMID M,et al. Contin-ued low-dose decitabine (DAC) is an active first-Linetreatement of older AML patients : first results of amulticenter phase-study [J ]. Blood, 2005, 106: 527 —527.
  • 7CASHEN A,SCHILLER G J,LARSEN J S,et al.Phase-study of low dose decitabine for the front linetreatment of older patients with acute myeloid leuke-mia(AML)[J]. Blood,2006,108:561 — 561.
  • 8CHOWDHURY S,SEROPIAN S, MARKS I W.Decitabine combined with fractionated gemtuzum abo-zogamicin therapy in patients with relapsed or refrac-tory acute myeloid leukemia[J]. Am J Hematol?2009,84:599-600.
  • 9I,WIJERMANS P W. Decitabinein in myel-odysplastic syndroms [J]. Semin Hematol,2005,42:23-31.
  • 10ISSA J P,GARCIA-MANERO G, GILES F J , et al.Phase I study of low-dose prolonged exposure sched-ules of the hypometylating agent 5-aza-2-deoxycyti-dine ( decitabine) in hematopoietic malignancies [ J ].Blood,2004 ,103:1635 —1640.

共引文献319

同被引文献98

引证文献10

二级引证文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部